Paper Details

  1. Home
  2. Paper Details

Cardiovascular effects of current and future anti-obesity drugs.

Author: AndersenCharlotte U, Comerma-SteffensenSimon, GrannMartin, RungbyJorgen, SimonsenUlf

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Obesity is linked to various health issues, and there is a need for safe and effective treatments. Anti-obesity drugs like fenfluramine and sibutramine were withdrawn due to cardiovascular risks, and rimonobant was withdrawn due to psychiatric problems. Current treatments like orlistat, phentermine, topiramate, and lorcaserin have limited efficacy and potential cardiovascular side effects. Drugs for type 2 diabetes, such as GLP-1 analogues and metformin, can cause moderate weight loss and have a favorable cardiovascular profile.
Paper Details　
Original Abstract of the Article :
The prevalence of obesity increases and is associated with increases in co-morbidities e.g. type 2 diabetes, hyperlipidemia, hypertension, obstructive sleep apnea, heart disease, stroke, asthma, several forms of cancer, depression, and may result in reduction of expected remaining lifespan. We have ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2174/1570161112666140423223529

データ提供：米国国立医学図書館（NLM）

The Cardiovascular Effects of Anti-Obesity Drugs: A Desert of Options

The field of anti-obesity medications is a vast desert, with a limited number of oases offering effective solutions. This research digs into the cardiovascular effects of various anti-obesity drugs, both past and present, using a methodical approach. It's like exploring a desert and examining the impact of various plants on the surrounding ecosystem. The authors conducted a comprehensive review of drugs that have been withdrawn due to cardiovascular risks, as well as those currently available and potential new pathways for treatment. They found that while some drugs like fenfluramine and sibutramine were removed from the market due to increased cardiovascular risk, others like rimonobant were withdrawn due to serious psychiatric problems. At present, there are only a few options left standing, including orlistat, phentermine, and lorcaserin. However, the cardiovascular side effects of these medications need further investigation. The study also examines potential anti-obesity pathways, including sirtuin activation and CB1 antagonists, but highlights that their cardiovascular profiles need more thorough exploration.

A Shifting Sandscape in Anti-Obesity Treatment

This research reveals that the landscape of anti-obesity treatment is constantly shifting, like the sands of a desert. While some drugs have fallen by the wayside due to adverse effects, new possibilities are emerging. Drugs approved for type 2 diabetes, such as GLP-1 analogues and metformin, can also lead to moderate weight loss and have a favorable cardiovascular profile. This suggests that exploring existing medications for new applications is a promising avenue for future research.

Navigating the Oasis of Anti-Obesity Medications

For those navigating the desert of obesity, this study offers a valuable roadmap. It emphasizes the importance of understanding the cardiovascular risks associated with various anti-obesity medications. The study reminds us to look beyond the oasis of weight loss and consider the long-term impact of these drugs on our overall health.

Dr.Camel's Conclusion

This research sheds light on the complex and ever-changing landscape of anti-obesity treatment. It reminds us that finding a safe and effective solution for obesity is a challenging journey, much like traversing a vast desert. The study highlights the importance of continued research and a cautious approach when evaluating new treatments, ensuring that we are not simply chasing mirages in the desert.

Date :
  1. Date Completed 2015-01-05
  2. Date Revised 2019-10-27
Further Info :

Pubmed ID

24846238

DOI: Digital Object Identifier

10.2174/1570161112666140423223529

Related Literature

Article Analysis
・Side Effects of nebivolol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.